Table 5. Selected combination chemotherapy regimens in MPM.
| Author, year | Regimen | n | Response rate (%) | Median survival (months) | Time to PD (months) | 1-year survival (%) |
|---|---|---|---|---|---|---|
| Current study | CDDP+vinorelbine | 54 | 29.6 | 16.8 | 7.2 | 61 |
| van Meerbeeck, 2005 a | CDDP+raltitrexed | 126 | 24.0 | 11.4 | 5.3 | 46 |
| Vogelzang, 2003 a | CDDP+pemetrexed | 226 | 41.3 | 12.1 | 5.7 | 51 |
| Obasaju, 2007 | CDDP+pemetrexed | 728 | 20.5 | 10.8 | NA | 45 |
| Santoro, 2007 | CBDCA+pemetrexed | 861 | 21.7 | NA | NA | 64 |
| Ceresoli, 2006b | CBDCA+pemetrexed | 102 | 18.6 | 12.7 | 6.5 | 52 |
| Andreopoulou, 2004 | CDDP+MMC+VBL | 150 | 15.3 | 7.0 | NA | 31 |
| Byrne, 1999 | CDDP+gemcitabine | 21 | 48.0 | 10.0 | NA | NA |
| van Haarst, 2002 | CDDP+gemcitabine | 32 | 16.0 | 9.6 | 6.0 | 36 |
| Favaretto, 2003 | CBDCA+gemcitabine | 50 | 26.0 | 14.7 | 8.9 | 53 |
| Berghmans, 2005 | CDDP+epirubicin | 69 | 19.0 | 13.3 | NA | 50 |
Abbreviations: CDDP=cisplatin; CBDCA=carboplatin; MMC=mitomycin C; VBL=vinblastine; NA=not available.
a
Data from randomised trial.